We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment.
- Authors
Skinner-Adams, Tina S.; Butterworth, Alice S.; Porter, Kimberly A.; D'Amico, Ronald; Sawe, Fred; Shaffer, Doug; Siika, Abraham; Hosseinipour, Mina C.; Stringer, Elizabeth; Currier, Judith S.; Chipato, Tsungai; Salata, Robert; Lockman, Shahin; Eron, Joseph J.; Meshnick, Steven R.; McCarthy, James S.
- Abstract
HIV protease inhibitors (PIs) show antimalarial activity in vitro and in animals. Whether this translates into a clinical benefit in HIV-infected patients residing in malaria-endemic regions is unknown. We studied the incidence of malaria, as defined by blood smear positivity or a positive Plasmodium falciparum histidine-rich protein 2 antigen test, among 444 HIV-infected women initiating antiretroviral treatment (ART) in the OCTANE trial (A5208; ClinicalTrials.gov: NCT00089505). Participants were randomized to treatment with PI-containing vs. PI-sparing ART, and were followed prospectively for ≥48 weeks; 73% also received cotrimoxazole prophylaxis. PI-containing treatment was not associated with protection against malaria in this study population.
- Subjects
MALARIA; ANTIRETROVIRAL agents; LOPINAVIR-ritonavir; NEVIRAPINE; HIV-positive persons; PROTEINS; ANTIGENS; PLASMODIUM falciparum
- Publication
PLoS ONE, 2012, Vol 7, Issue 4, p1
- ISSN
1932-6203
- Publication type
Article
- DOI
10.1371/journal.pone.0034399